Strug­gling Heat gets a warm re­sponse to a snap­shot on can­cer vax da­ta

Heat Bi­o­log­ics man­aged to at least tem­porar­i­ly ex­tri­cate it­self from pen­ny stock ter­ri­to­ry af­ter of­fer­ing a pos­i­tive up­date on its com­bi­na­tion study for non-small cell lung can­cer. Its stock surged more than 20% this morn­ing based on an up­date for a hand­ful of pa­tients tak­ing a com­bi­na­tion of HS-110 and Bris­tol-My­ers Squibb’s check­point in­hibitor Op­di­vo.

The up­dat­ed snap­shot from the Durham, NC-based biotech in­clud­ed a note that 3 of 5 pa­tients en­rolled in a co­hort for low tu­mor in­fil­trat­ing lym­pho­cytes “ex­pe­ri­enced sig­nif­i­cant tu­mor re­duc­tion, which is high­er than the 10% re­sponse rate of low TIL pa­tients re­port­ed for ex­ist­ing da­ta on nivolum­ab alone.” 5 of 12 evalu­able pa­tients ex­pe­ri­enced an im­mune re­sponse to the com­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER